Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate-2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.
Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA. GAR2001@med.cornell.edu
Gail J
GJ
Roboz
Ellen K
EK
Ritchie
Tania
T
Curcio
Michael
M
Samuel
Juliette
J
Provenzano
Javier
J
Segovia
Paul J
PJ
Christos
Susan
S
Mathew
Sandra
S
Allen-Bard
Eric J
EJ
Feldman
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009325:Nausea / Q000139:chemically induced; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D001152:Arsenicals; D010087:Oxides; D003561:Cytarabine; D000077237:Arsenic Trioxide